WO2001045690A3 - Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes - Google Patents

Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes Download PDF

Info

Publication number
WO2001045690A3
WO2001045690A3 PCT/US2000/035027 US0035027W WO0145690A3 WO 2001045690 A3 WO2001045690 A3 WO 2001045690A3 US 0035027 W US0035027 W US 0035027W WO 0145690 A3 WO0145690 A3 WO 0145690A3
Authority
WO
WIPO (PCT)
Prior art keywords
bvdu
cell
provides methods
hyperproliferative cells
hyperproliferative
Prior art date
Application number
PCT/US2000/035027
Other languages
English (en)
Other versions
WO2001045690A2 (fr
Inventor
Christopher Boyer
David Bruce Lackey
Original Assignee
New Biotics Inc
Christopher Boyer
David Bruce Lackey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Biotics Inc, Christopher Boyer, David Bruce Lackey filed Critical New Biotics Inc
Priority to EP00988293A priority Critical patent/EP1251836A2/fr
Priority to US10/168,722 priority patent/US20030212037A1/en
Priority to AU24516/01A priority patent/AU2451601A/en
Publication of WO2001045690A2 publication Critical patent/WO2001045690A2/fr
Publication of WO2001045690A3 publication Critical patent/WO2001045690A3/fr
Priority to US11/627,341 priority patent/US20070155673A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés permettant de tuer de manière sélective une cellule hyperproliférante, par la mise en contact de la cellule avec le composé BVdU, des dérivés ou des sels pharmaceutiquement acceptables de celui-ci. L'invention concerne de plus une méthode permettant de traiter chez un sujet une pathologie caractérisée par des cellules pathologiques hyperproliférantes, par l'administration à ce sujet d'une quantité efficace du composé BVdU, de dérivés ou de sels pharmaceutiquement acceptables de celui-ci. L'invention concerne également une méthode de criblage d'agents thérapeutiques potentiels, qui comporte la mise en contact d'une cellule néoplasique avec l'agent et avec le composé BVdU, et la mise en oeuvre d'un dosage pour détecter l'inhibition de la prolifération et la mort de la cellule. L'invention a également trait à des procédés visant à sélectionner dans une population de patients ceux qui sont susceptibles de tirer profit d'un traitement à l'aide de BVdU, par la détermination des taux de TK et de TS endogène intracellulaire. L'invention se réfère aussi à des procédés de sensibilisation de patients aux effets thérapeutiques de BVdU par un traitement à l'aide de substances entraînant une augmentation des taux de TK dans les cellules hyperproliférantes.
PCT/US2000/035027 1999-12-23 2000-12-21 Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes WO2001045690A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00988293A EP1251836A2 (fr) 1999-12-23 2000-12-21 Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes
US10/168,722 US20030212037A1 (en) 2000-12-21 2000-12-21 Use of bvdu for inhibiting the growth of hyperproliferative cells
AU24516/01A AU2451601A (en) 1999-12-23 2000-12-21 Use of bvdu for inhibiting the growth of hyperproliferative cells
US11/627,341 US20070155673A1 (en) 1999-12-23 2007-01-25 Use of bvdu for inhibiting the growth of hyperproliferative cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17197199P 1999-12-23 1999-12-23
US60/171,971 1999-12-23
US17399699P 1999-12-30 1999-12-30
US60/173,996 1999-12-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/954,797 Continuation US20050080035A1 (en) 1999-12-23 2004-09-29 Use of BVDU for inhibiting the growth of hyperproliferative cells

Publications (2)

Publication Number Publication Date
WO2001045690A2 WO2001045690A2 (fr) 2001-06-28
WO2001045690A3 true WO2001045690A3 (fr) 2002-07-25

Family

ID=26867621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035027 WO2001045690A2 (fr) 1999-12-23 2000-12-21 Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes

Country Status (3)

Country Link
EP (1) EP1251836A2 (fr)
AU (1) AU2451601A (fr)
WO (1) WO2001045690A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095294A1 (fr) * 1982-05-22 1983-11-30 Beecham Group Plc Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
EP0283065A1 (fr) * 1987-02-13 1988-09-21 Stichting REGA V.Z.W. Associations de FU et BVU comme agents antiadénocarcinomes
WO1996023506A1 (fr) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Utilisation de nucleosides substitues en position 5' pour attenuer les phenomenes de resistance lors de traitements par agents cytostatiques, et medicaments contenant ces nucleosides
WO1999037753A1 (fr) * 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095294A1 (fr) * 1982-05-22 1983-11-30 Beecham Group Plc Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
EP0283065A1 (fr) * 1987-02-13 1988-09-21 Stichting REGA V.Z.W. Associations de FU et BVU comme agents antiadénocarcinomes
WO1996023506A1 (fr) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Utilisation de nucleosides substitues en position 5' pour attenuer les phenomenes de resistance lors de traitements par agents cytostatiques, et medicaments contenant ces nucleosides
WO1999037753A1 (fr) * 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALZARINI J. ET AL.: "Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammalry carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene", MOLECULAR PHARMACOLOGY, vol. 28, no. 6, 1985, pages 581 - 587, XP000563717 *
WILDNER O., ET AL.: "Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of the colon cancer", CANCER RESEARCH, vol. 59, no. 20, 15 October 1999 (1999-10-15), pages 5233 - 5238, XP001002739 *

Also Published As

Publication number Publication date
AU2451601A (en) 2001-07-03
EP1251836A2 (fr) 2002-10-30
WO2001045690A2 (fr) 2001-06-28

Similar Documents

Publication Publication Date Title
Minami et al. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity
Wang et al. Paclitaxel‐induced cell death: where the cell cycle and apoptosis come together
RU2009144142A (ru) Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
KR20040078663A (ko) 난청의 치료 방법
EP2872128A1 (fr) Nicotinamide riboside pour traiter la perte auditive
IL197296A0 (en) Use of imatinab for the manufacture of a medicament for the treatment of philadelphia positive -leukemia
MXPA05013974A (es) Formulaciones farmaceuticas de compuestos de inhibicion amiloidea.
WO2003048122A3 (fr) Inhibiteurs de phospholipase a2 cytosolique
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
WO2002047673A3 (fr) Methodes et compositions pour le traitement d'etats pathologiques associes a la neovascularisation
AU2005226901A1 (en) Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
WO2001045690A3 (fr) Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes
Li et al. Topical application of a dual ABC transporter substrate and NF-κB inhibitor blocks multiple sources of cutaneous inflammation in mouse skin
WO2004024089A3 (fr) Inhibition ou activation des proteines adam9 et adam15 pour le traitement des maladies liees a la vascularisation et la guerison des blessures
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
Caillier et al. Metabolic syndrome potentiates the cardiac action potential-prolonging action of drugs: a possible ‘anti-proarrhythmic’role for amlodipine
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2000020582A3 (fr) Therapie par remplacement de genes pour dystrophie musculaire
Rajagopalan et al. Radiosensitizer Sanazole (AK-2123) enhances γ-radiation-induced Apoptosis in murine fibrosarcoma
Ciociola et al. Peyronie’s disease: A “triple oxygenant therapy”
Straub et al. Effects of nifedipine on rhythmic synchronous activity of human neocortical slices
Ou et al. Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate
WO2004012677A3 (fr) Procedes et compositions pour le traitement d'etats associes a la neovascularisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000988293

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000988293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10168722

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000988293

Country of ref document: EP